




RealRate

PHARMACEUTICAL 2015

Sonoma Pharmaceuticals Inc
Rank 115 of 274



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 305%, being 51% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	9,542
Cost of Goods Sold	5,271
Intangible Assets	0
Liabilities, Current	7,572
Liabilities, Non-Current	4.0
Other Assets	10,278
Other Compr. Net Income	-78
Other Expenses	1,139
Other Liabilities	1,152
Other Net Income	10,925
Other Revenues	13,668
Property and Equipment	971
Research and Development	2,887
Selling, General and Administrative Expense	11,561

Output Variable	Value in 1000 USD
Assets	20,791
Liabilities	8,728
Expenses	20,858
Revenues	13,668
Stockholders Equity	12,063
Net Income	3,735
Comprehensive Net Income	3,696
BaseVar	37,524
ECR before LimitedLiability	203%
Economic Capital Ratio	305%